This report focuses on the global Pigmentation Disorders Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Pigmentation Disorders Treatment development in United States, Europe and China.



Pigmentation therapies can be classified as topical drugs, microdermabrasion, chemical peels, phototherapy, and laser therapy. These therapies are available in hospitals and aesthetic clinics & dermatology centers.

The pigmentation disorder treatment market has been segmented based on treatment, disease indication, end-user, and region. In terms of treatment, the topical drugs segment is estimated to account for a prominent share of the market. An increasing number of patients with pigmentation disorders are visiting dermatologists, and topical drugs are being prescribed to these patients. With an existing unmet need for better treatment armamentarium for severe, recalcitrant patients and an estimated drug-treated population that is expected to double over the next decade, topical drugs is an attractive segment for drug developers. This is expected to fuel commercial interest in the development of tropical drugs.

Based on disease indication, the vitiligo and melasma segment constituted a major share of the market in 2017. The segment is likely to expand at a significant growth rate as compared to other disease indication segments during the forecast period. Globally, the prevalence of vitiligo and melasma varies. Women are far more likely to be affected by melisma than men, and both sexes are affected equally by vitiligo. In pigmentation, inadequate patient compliance still remains a significant unmet need. This single factor has hindered the ability of patients to achieve maximum treatment benefit, given the therapeutic options currently available, and has resulted in multiple failed treatment attempts.


The Pigmentation Disorder Treatment market has been experiencing steady growth graph since past years. During the 2017-2025 timeline, the global market for Pigmentation Disorder Treatment is expected to reflect a 1.7x increase in the revenue growth. In 2017 the global Pigmentation Disorders market was valued at US$ 5,285 Mn and by the end of the assessment year (2025), it is estimated to touch a value more than US$ 8,912 Mn growing at a value CAGR of 6.75% throughout the period of forecast.





The key players covered in this study

Bayer AG

ALLERGAN

Galderma S.A

SkinCeuticals

Pierre Fabre

EpiPharm AG

RXi Pharmaceuticals Corporation

Obagi Cosmeceuticals LLC

Vivier Pharma



Market segment by Type, the product can be split into

Topical Drugs

Microdermabrasion

Chemical Peels

Phototherapy

Laser Therapy



Market segment by Application, split into

Men

Women



Market segment by Regions/Countries, this report covers

United States

Europe

China

Japan

Southeast Asia

India

Central & South America



The study objectives of this report are:

To analyze global Pigmentation Disorders Treatment status, future forecast, growth opportunity, key market and key players.

To present the Pigmentation Disorders Treatment development in United States, Europe and China.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by product type, market and key regions.



In this study, the years considered to estimate the market size of Pigmentation Disorders Treatment are as follows:

History Year: 2013-2017

Base Year: 2017

Estimated Year: 2018

Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.